Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Paesmans, C. Y. O. Wong, E. F. Patz, R. Komaki, S. Eschmann, R. Govindan, J. Vansteenkiste, A. P. Meert, W. de Jong, K. Higashi, G. Borst, A. Van Baardwijk, L. Ameye, J. J. Lafitte, T. Berghmans, C. Garcia, P. Flamen, R. Rami Porta, J. P. Sculier (Brussels, Leuven, Belgium; Royal Oak, Durham, Houston, St-Louis, United States Of America; Tubingen, Germany; Groningen, Amsterdam, Maastricht, Netherlands; Ishikawa, Japan; Lille, France; Barcelona, Spain). Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data. Eur Respir J 2011; 38: Suppl. 55, 2750

Member's Comments

No comment yet.

Related content which might interest you: Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data Source: Eur Respir J 2015; 46: 1751-1761 Year: 2015 Validation and comparison of several published prognostic systems for patients with small cell lung cancer Source: Eur Respir J 2011; 38: 657-663 Year: 2011 Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 The prognostic value of the albumin-to-fibrinogen ratio in lung cancer patients. Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Prognostic value of mean platelet volume in non-small cell lung cancer: a real-world, registry-based study Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer Year: 2019 Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Small cell lung cancer: prognostic significance and correlation with clinical and laboratory parameters Source: Eur Respir J 2007; 30: Suppl. 51, 670s Year: 2007 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 C-kit (CD 117): a new prognostic factor in small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 HER2/Neu overexpression as independent negative prognostic factor for non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Source: Eur Respir J 2001; 18: 705-719 Year: 2001 The role of angiogenesis, assessed by microvessel count (MVC), on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Source: Eur Respir J 2002; 20: Suppl. 38, 3s Year: 2002 Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006